Corcept’s (CORT) Multibagger Momentum Builds on Relacorilant and Expanding Commercial Footprint

Corcept Therapeutics Inc. (NASDAQ:CORT) is one of the best multibagger stocks to invest in right now. The company has recently revised its 2025 revenue guidance to $850-$900 million, down from the previous range of $900-$950 million. Despite the adjustment, management reiterated confidence in the company’s growth trajectory, pointing to contributions from an expanded sales force, new pharmacy partnerships, and progress in its pipeline. Corcept's (CORT) Multibagger Momentum Builds on Relacorilant and Expan ...